NYSE American LLC informed iBio Inc. that the company had regained compliance with all of the stock exchange's listing standards.

The New York-based biotechnology company received a noncompliance notice in June after its stockholders' equity fell below the exchange's minimum requirement of $6 million and it booked net losses in five of its most recent fiscal years.

In August, NYSE American accepted iBio's plan to regain compliance with the stock exchange, which had a deadline of Dec. 6, 2019.

IBio provides product development and manufacturing services to clients, collaborators, and third-party customers.